AMD

The complement pathway in geographic atrophy explained

Examining the role of complement factors in advanced disease.

The promise of targeting mitochondria in dry AMD

Mitochondrial therapies have shown the potential to improve visual function in patients with dry age-related macular degeneration.

Understanding role of Ang2 in neovascular AMD

Angiopoietin-2 is an increasingly desirable target in age-related macular degeneration. Here’s why, and an assessment of investigative treatments.

Lessons from CANTREAT: fewer visits, BCVA improvement

Level 1 evidence now supports treat-and-extend vs. monthly intervals for anti-VEGF treatment of neovascular age-related macular degeneration.

Potential of OCT to identify genetic risk in AMD

A look at our work in optical coherence tomography-derived drusen burden in non-advanced age-related macular degeneration.

Has the time come for AMD home monitoring?

An update on the progress of home-based OCT and how it could reduce treatment burden during and beyond the pandemic.

Long-term anti-VEGF effect: Six questions answered

A review of the evidence that suggests the beneficial effects of consistent treatment extend out to 10 years.

Potential of OCT to identify genetic risk in AMD

A look at our work in optical coherence tomography-derived drusen burden in non-advanced age-related macular degeneration.

More frequent dosing for refractory nAMD?

A closer look at biweekly anti-VEGF dosing for chronic disease that doesn’t respond completely to standard monthly dosing.

New revelations for nAMD, CSC treatments and ILM utility

Trial readouts on improving treatment durability, a potential new therapy for central serous chorioretinopathy and adding to the debate of RRD repair.

Video Vault

Minimally invasive management of lenticular deposits

Akshay Thomas, MD, MS, of Tennessee Retina demonstrates his surgical technique for removing posterior intraocular lens deposits.